Investing

Proceeds from Sale of Equity Method Investments

Pfizer Proceeds from Sale of Equity Method Investments decreased by 100.0% to $0.00 in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 100.0%, from $6.31B to $0.00.

Analysis

StatementCash Flow Statement
SectionInvesting
First reportedQ1 2022
Last reportedQ1 2026May 5, 2026
Metric ID: mrk_proceeds_sale_equity_method_investments

Historical Data

12 periods
 Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q4 '24Q1 '25Q1 '26
Value$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$3.49B$3.55B$6.31B$0.00
QoQ Change+1.7%+77.8%-100.0%
YoY Change+80.8%-100.0%
Range$0.00$6.31B
Avg YoY Growth-9.6%
Median YoY Growth-9.6%

Frequently Asked Questions

What is Pfizer's proceeds from sale of equity method investments?
Pfizer (PFE) reported proceeds from sale of equity method investments of $0.00 in Q1 2026.
How has Pfizer's proceeds from sale of equity method investments changed year-over-year?
Pfizer's proceeds from sale of equity method investments decreased by 100.0% year-over-year, from $6.31B to $0.00.